findmyKOL
Clinical trialNCT06511882RecruitingPhase 2Interventional

Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD

SponsorH. Lee Moffitt Cancer Center and Research InstituteEnrollment37Acute Myeloid Leukemia
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Moffitt Cancer Center

    Tampa, Florida, United States

    Alison Walker, MDAndrew Kuykendall, MDDavid Sallman, MDEric Padron, MDJeffrey Lancet, MDOnyee Chan, MDRami Komrokji, MDTimothy Kubal, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Azacitidine →Decitabine →Venetoclax →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
7 Nov 2024
Primary completion
31 Oct 2027
Completion
31 Aug 2028
Last update posted
27 Feb 2026
Registered enrollment
37
Registry id
NCT06511882
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.